Combination use of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders

Details for Australian Patent Application No. 2001294117 (hide)

Owner Pfizer Products Inc. Neurogen Corporation

Inventors Villalobos, Anabella; Cassella, James Vincent; Rajachandran, Lavanya

Agent Spruson & Ferguson

Pub. Number AU-B-2001294117

PCT Pub. Number WO02/32412

Priority 60/241,145 17.10.00 US

Filing date 15 October 2001

Wipo publication date 29 April 2002

Acceptance publication date 27 July 2006

International Classifications

A61K 31/00 (2006.01)

A61K 31/195 (2006.01)

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/47 (2006.01) - Quinolines

A61K 31/55 (2006.01) - having seven-membered rings, e.g. azelastine, pentylenetetrazole

A61K 31/66 (2006.01) - Phosphorus compounds

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

27 July 2006 Application Accepted

  Published as AU-B-2001294117

23 November 2006 Standard Patent Sealed

14 May 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2001294118

2001294116